Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Censa Pharmaceuticals is a late-stage pharmaceutical company developing CNSA-001 for the treatment of phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin biochemical pathways. Censa is Developing Medicines to Improve the Lives of Patients with Debilitating Diseases.

List your booth number for exhibitions, ask us